Morgan Stanley Has Lowered Expectations for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target cut by analysts at Morgan Stanley from $400.00 to $300.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price target would indicate a potential upside of 48.11% from the stock’s current price.

A number of other equities research analysts have also issued reports on the stock. Stifel Nicolaus dropped their price objective on shares of Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating for the company in a report on Friday. HC Wainwright reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Friday. Citigroup began coverage on shares of Alnylam Pharmaceuticals in a report on Tuesday, May 19th. They issued a “buy” rating and a $380.00 target price on the stock. Chardan Capital reissued a “buy” rating and issued a $425.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday. Finally, JPMorgan Chase & Co. cut their price target on shares of Alnylam Pharmaceuticals from $420.00 to $400.00 and set an “overweight” rating for the company in a report on Wednesday, July 22nd. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $423.70.

Alnylam Pharmaceuticals Price Performance

ALNY stock traded down $2.92 during mid-day trading on Friday, reaching $202.56. 2,236,666 shares of the company’s stock were exchanged, compared to its average volume of 1,366,600. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. Alnylam Pharmaceuticals has a 12-month low of $197.81 and a 12-month high of $495.55. The stock’s 50 day moving average is $289.80 and its 200 day moving average is $312.07. The company has a market cap of $27.04 billion, a price-to-earnings ratio of 55.35 and a beta of 0.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The company had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter in the previous year, the company posted ($0.44) EPS. The firm’s quarterly revenue was up 96.4% on a year-over-year basis. On average, research analysts expect that Alnylam Pharmaceuticals will post 7.35 EPS for the current year.

Insider Activity

In other news, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the transaction, the director directly owned 1,582 shares in the company, valued at $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is currently owned by corporate insiders.

Institutional Trading of Alnylam Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 6.1% during the fourth quarter. Geode Capital Management LLC now owns 2,650,722 shares of the biopharmaceutical company’s stock worth $1,056,884,000 after purchasing an additional 151,480 shares during the last quarter. Norges Bank acquired a new position in Alnylam Pharmaceuticals in the fourth quarter valued at $895,816,000. Orbis Allan Gray Ltd lifted its position in Alnylam Pharmaceuticals by 29.8% during the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after buying an additional 486,489 shares during the period. Legal & General Group Plc lifted its position in Alnylam Pharmaceuticals by 8.3% during the fourth quarter. Legal & General Group Plc now owns 961,496 shares of the biopharmaceutical company’s stock worth $382,339,000 after buying an additional 73,716 shares during the period. Finally, AQR Capital Management LLC boosted its stake in Alnylam Pharmaceuticals by 23.6% in the 4th quarter. AQR Capital Management LLC now owns 919,959 shares of the biopharmaceutical company’s stock worth $365,822,000 after buying an additional 175,951 shares during the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

More Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Alnylam reported second-quarter adjusted earnings of $1.84 per share, above the $1.63 consensus estimate, while revenue rose 66.9% year over year to $1.29 billion. The company also highlighted continued strength in its transthyretin (TTR) business. Alnylam quarterly earnings report
• Positive Sentiment: Analysts continue to see substantial long-term value despite lowering estimates. Stifel maintained a “buy” rating with a $318 price target, Needham retained “buy” with a $357 target, and Chardan reaffirmed “buy” with a $425 target. Analyst rating updates
• Neutral Sentiment: Alnylam’s 2026 revenue guidance is now $5.3 billion to $5.7 billion, broadly around the $5.6 billion analyst consensus, but the range and commentary indicate reduced confidence in near-term growth. Alnylam lowers 2026 outlook
• Neutral Sentiment: Several law firms announced securities-fraud investigations following the selloff. These announcements are generally shareholder-solicitation notices and do not establish wrongdoing, but they add headline and potential litigation risk. Securities fraud investigation announcement
• Negative Sentiment: Second-quarter revenue of $1.29 billion missed the $1.32 billion consensus, and another report placed EPS at $1.84 versus a $2.05 estimate. The combination of the revenue miss and lower Amvuttra/ATTR-CM expectations prompted multiple analysts to cut price targets, including Wells Fargo to $316 and Stifel to $318. Alnylam Amvuttra outlook article

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.